These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 16022188

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
    Rester U.
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
    [Abstract] [Full Text] [Related]

  • 3. Novel trends in high-throughput screening.
    Mayr LM, Bojanic D.
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [Abstract] [Full Text] [Related]

  • 4. Crystallography, NMR and virtual screening: integrated tools for drug discovery.
    Muchmore SW, Hajduk PJ.
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):544-9. PubMed ID: 12951817
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions.
    Huber W.
    J Mol Recognit; 2005 Jul; 18(4):273-81. PubMed ID: 15997470
    [Abstract] [Full Text] [Related]

  • 7. A novel in silico approach to drug discovery via computational intelligence.
    Hecht D, Fogel GB.
    J Chem Inf Model; 2009 Apr; 49(4):1105-21. PubMed ID: 19348414
    [Abstract] [Full Text] [Related]

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High-throughput X-ray crystallography for drug discovery.
    Blundell TL, Patel S.
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [Abstract] [Full Text] [Related]

  • 13. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design.
    Davis AM, Teague SJ, Kleywegt GJ.
    Angew Chem Int Ed Engl; 2003 Jun 23; 42(24):2718-36. PubMed ID: 12820253
    [Abstract] [Full Text] [Related]

  • 14. Pursuing the leadlikeness concept in pharmaceutical research.
    Hann MM, Oprea TI.
    Curr Opin Chem Biol; 2004 Jun 23; 8(3):255-63. PubMed ID: 15183323
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In silico prediction of ADME properties: are we making progress?
    Beresford AP, Segall M, Tarbit MH.
    Curr Opin Drug Discov Devel; 2004 Jan 23; 7(1):36-42. PubMed ID: 14982146
    [Abstract] [Full Text] [Related]

  • 17. Designer drugs: the evolving science of drug discovery.
    Wanke LA, DuBose RF.
    Pharm Pract Manag Q; 1998 Jul 23; 18(2):13-22. PubMed ID: 10185235
    [Abstract] [Full Text] [Related]

  • 18. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C, Ottl J.
    Expert Opin Drug Discov; 2010 Nov 23; 5(11):1095-107. PubMed ID: 22827747
    [Abstract] [Full Text] [Related]

  • 19. Integration of fragment screening and library design.
    Siegal G, Ab E, Schultz J.
    Drug Discov Today; 2007 Dec 23; 12(23-24):1032-9. PubMed ID: 18061882
    [Abstract] [Full Text] [Related]

  • 20. Process technologies for purity enhancement of large discovery libraries.
    Pottorf RS, Player MR.
    Curr Opin Drug Discov Devel; 2004 Nov 23; 7(6):777-83. PubMed ID: 15595438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.